retatrutide trial results 2025 news Yep, Lilly’s showing us how it’s done. Just as we have been anticipating and expecting, they have phenomenal from their phase 3 of Retatrutide, a triple agonist that activates GLP1, GIP, This is exciting. 👀 The

These medications have resulted in extreme weight loss and not surprisingly, are immensely popular

Use this week to double down on meal prep, confirm your exercise schedule, and set up your monitoring systems

Our job is finding out whether (and where) were priced to perfection

Our goal is to provide you with the knowledge needed to have an informed conversation with a medical professional

You can contact Kaiser Pharmacy Services in your region to confirm your medication benefits and out-of-pocket costs

KFFs latest Health Tracking Poll provides an update to last years poll measuring public use of GLP-1 agonists a class of drugs that includes brand names like Ozempic and Wegovy often used for weight loss and the treatment of diabetes and other chronic conditions